Daewoong Pharma Submits NDA for Diabetes Combo 'Enblozem' Based on Positive Phase 3 Results, Boosting New Product Launch Prospects
Daewoong Pharma disclosed on May 26, 2026, that it submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for 'Enblozem Tab. 0.3/50mg' (enavogliflozin/gemigliptin combination) for type 2 diabetes.
The submission is based on a Phase 3 trial in patients inadequately controlled on metformin and gemigliptin. The test group (DWP16001 0.3mg) showed a -0.92%p reduction in HbA1c at 24 weeks, demonstrating non-inferiority vs. dapagliflozin 10mg (-0.86%p) (95% CI: -0.19~0.06, below non-inferiority margin of 0.35%p). Adverse event rates were similar (21.64% vs. 23.53%).
A Phase 1 trial confirmed pharmacokinetic equivalence between the combination (DWJ1563) and co-administration of individual components, supporting the combination rationale.
Daewoong plans to establish marketing strategies and launch the product upon approval. The designation as an improved new drug will be determined by the MFDS.
However, the NDA does not guarantee final approval, and unexpected outcomes during review are possible. Investors should consider these risks.
[AI Comprehensive Analysis]This NDA submission is a key milestone for Daewoong's diabetes pipeline expansion, but uncertainties remain until final approval and market entry. Short-term stock momentum is possible, but long-term value depends on future sales and competitive landscape.
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (Application for Domestic Product Approval of Envlozem)